ProfileGDS5678 / 1417075_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 83% 80% 83% 81% 80% 77% 81% 85% 82% 81% 82% 80% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6523280
GSM967853U87-EV human glioblastoma xenograft - Control 26.1498783
GSM967854U87-EV human glioblastoma xenograft - Control 35.6741980
GSM967855U87-EV human glioblastoma xenograft - Control 46.2714783
GSM967856U87-EV human glioblastoma xenograft - Control 55.8415681
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4533780
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1361777
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8080481
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2753485
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9986782
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8392281
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9616382
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5984180
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0332183